Compare
NAVs as of 20 Aug 2026
Add a second fund to compare. Until then every figure below is shown against the Sectoral/ Thematic median (252 funds), which is the only comparison one fund can support.
Growth of ₹100 (rebased over the selected window)
Common period 18 Dec 2024 – 20 Aug 2026, limited by DSP Business Cycle Fund. Every series is rebased to ₹100 at the start of this window. Benchmark lines are the category index WealthTicker measures against, which is not always the benchmark the scheme itself declares — the fund page’s Scheme Info names that one.
View as table
| Date | DSP Business Cycle Fund | Nifty 500 |
|---|---|---|
| 18 Dec 2024 | ₹100.00 | ₹100.00 |
| 07 Feb 2025 | ₹94.42 | ₹94.38 |
| 30 Mar 2025 | ₹93.67 | ₹93.05 |
| 20 May 2025 | ₹97.57 | ₹98.48 |
| 09 Jul 2025 | ₹102.93 | ₹102.72 |
| 29 Aug 2025 | ₹98.66 | ₹97.94 |
| 19 Oct 2025 | ₹103.79 | ₹102.89 |
| 09 Dec 2025 | ₹103.61 | ₹102.54 |
| 29 Jan 2026 | ₹103.15 | ₹100.87 |
| 21 Mar 2026 | ₹97.32 | ₹93.00 |
| 10 May 2026 | ₹104.96 | ₹100.79 |
| 30 Jun 2026 | ₹105.75 | ₹100.27 |
| 20 Aug 2026 | ₹107.06 | ₹102.52 |
| Metric | DSP · Direct NAV ₹10.71 Very High risk ★★★☆☆ 1Y | Category median Sectoral/ Thematic · 252 funds |
|---|---|---|
| +5.24% | +7.23% | |
| — | +16.94% | |
| — | +14.70% | |
| — | +15.10% | |
| +4.17% | +14.07% | |
| +7.09% | — | |
| — | +17.59% | |
| — | +16.29% | |
| — | +16.00% | |
| Risk | ||
| 13.98% | 15.69% | |
| -0.09 | 0.52 | |
| -0.12 | 0.73 | |
| -14.77% | -23.08% | |
| Nifty 500 | — | |
| — | +4.66% | |
| — | 0.96 | |
| — | 109.1% | |
| — | 91.0% | |
| 1.27% | 1.14% | |
| ₹1,162Cr | ₹1,161Cr | |
| 0.50% | — | |
| None | — | |
| ₹100 | — | |
| ₹100 | — | |
| 91% | 45% | |
| Vinit Sambre | — | |
| 18 Dec 2024 | — | |
| 44 | — | |
| 47.6% | — | |
| 5.7% | — | |
Best marks the strongest value in a row, and only where the gap is bigger than noise — a near-tie is left unmarked rather than dressed up as a result. SIP XIRR is a ₹10,000/month instalment over 5 years of real NAV history. Nothing here is supplied by a fund house. For research only — not investment advice.